anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Robotic systems, such as Lokomat® have shown promising results in people with severe motor impairments, who suffered a stroke or other neurological damage. Robotic devices have also been used by people with more challenging damages, such as Spinal Cord Injury (SCI), using feedback strategies that provide information about the brain activity in real-time. This study proposes a novel Motor Imagery (MI)-based Electroencephalogram (EEG) Visual Neurofeedback (VNFB) system for Lokomat® to teach individuals how to modulate their own μ (8-12 Hz) and β (15-20 Hz) rhythms during passive walking. Two individuals with complete SCI tested our VNFB system completing a total of 12 sessions, each on different days. For evaluation, clinical outcomes before and after the intervention and brain connectivity were analyzed. As findings, the sensitivity related to light touch and painful discrimination increased for both individuals. Furthermore, an improvement in neurogenic bladder and bowel functions was observed according to the American Spinal Injury Association Impairment Scale, Neurogenic Bladder Symptom Score, and Gastrointestinal Symptom Rating Scale. Moreover, brain connectivity between different EEG locations significantly ( [Formula: see text]) increased, mainly in the motor cortex. As other highlight, both SCI individuals enhanced their μ rhythm, suggesting motor learning. These results indicate that our gait training approach may have substantial clinical benefits in complete SCI individuals.
The invention provides a preparation method of a high-stability and high-biosafety chitosan nano material (CMCS-PEI-PpIX nano particle) and application thereof in broad-spectrum photodynamic antimicrobial. Protoporphyrin (PpIX) and ethylene imine (PEI) are used as raw materials, and the PEI-PpIX is obtained by a one-step hydrothermal method. And then PEI-PpIX and carboxymethyl chitosan (CMCS) are used as raw materials to generate CMCS-PEI-PpIX with negative charges through EDC/NHS reaction. CMCS-PEI-PpIX self-assembles into nanoparticles in solution and shows significantly enhanced singlet oxygen production in solution. Therefore, the CMCS-PEI-PpIX nano particle has good antibacterial PDT activity on gram-negative bacteria, gram-positive bacteria and fungi, and is nontoxic and highly stable to normal cells. The invention provides an effective way for effectively killing disease microorganisms in food, medical supplies and food and medical processing environments.
The invention discloses an electronic archive big data mining health assessment method and system based on artificial intelligence. An electronic health file is obtained. And obtaining a file vector based on the electronic health file. And inputting the archive vector into a health assessment model, and performing health assessment to obtain a health assessment vector. And obtaining user health evaluation information based on the health evaluation vector. The health assessment model comprises a generating network, an information fusion structure and a discrimination network, wherein the generating network comprises a neural input layer, a first neural network hidden layer and a second neural network hidden layer, and the discrimination network comprises a first discrimination network and a second discrimination network. The method adopts a training method for generating an confrontation method and directly obtaining loss to train a generation network, so that the generation network is more accurate, and meanwhile, when the generation network is constructed, because the health information is better distinguished, the health information is output firstly, the number of the following neurons is reduced, and meanwhile, the calculation amount is reduced, so that the network is trained more quickly and accurately.
Retigabine Physicians (e.g. neurologists/epileptologists/neurosurgeons) who have prescribed retigabine at least once in the last 12 months.
PURPOSE:To obtain the subject parenteral solution, stable for a long period, capable of performing inspection of insoluble foreign materials and good in operating efficiency, etc., by dissolving an antipancreatitic medicine in a mixture solution of ethanol with propylene glycol and polyethylene glycol. CONSTITUTION:The objective parenteral solution is obtained by dissolving an antipancreatitic medicine such as 6-amidino-2-naphthyl-p-guanidinobenzoate dimethanesulfonate (NM) in a mixture solution of (A) ethanol with (B) propylene glycol and/or (C) polyethylene glycol. The antipancreatitic medicine is preferably dissolved in an amount of 1-5wt.% in the parenteral solution in the case of the NM. The ingredient (A) is preferably contained in an amount of 0.1-20wt.%. Furthermore, the other ingredients are preferably used in the following amounts: 5-8 pts.wt. ingredients (B) and/or (C) based on 1 pt.wt. ingredient (A) and 10-50 pts.wt. ingredient (C) based on 100 pts.wt. ingredient (B).
Embodiments herein include systems and methods for detecting, predicting and/or assessing acute kidney injury. In an embodiment, a monitoring system to detect acute kidney injury is included. The monitoring system can include a sensor circuit configured to collect renal data including at least one of systemic renal data, direct renal data, urinary tract data, and renal-relevant extracorporeal data. The monitoring system can also include a memory circuit to store collected renal data, an evaluation circuit to assess renal status, and a telemetry circuit. The evaluation circuit can determine whether acute kidney injury has occurred or is likely to occur by comparing the renal data to at least one of threshold values, personal historical values, patient population values and patterns indicative of acute kidney injury. The evaluation circuit can initiate a warning notification if acute kidney injury has occurred or is likely to occur. Other embodiments are also included herein.
Patients with work-related stress (F43.2/8/9 or Z56.3 (ICD-0)) who received the stress management intervention between 2011-2018 (N\>400). The intervention is based on cognitive behavioral therapy, delivered by a trained psychologist in groups of 8-10 patients. The intervention consists of 8 sessions in 3 months, with a booster session 3 months after the intervention has ended.
The present invention belongs to a processing technique for mercury containing compound medicine preparing articles. The present invention comprises the steps: purifying mercury, processing mercury powder and preparing medicinal powder. The mercury is ground with galangal, salt, trona, etc., and after washed, the mercury is decocted and purified in a stone pan with treated eight kinds of powder (gold, silver, copper, ferrum, tin, brass, red bronze and black and white aluminum), eight kinds of element powder (gold ore, silver ore, magnetite, websterite, pyrite, arsenic sulphide, realgar and mica), three kinds of acid water (hippophae rhamnoides solution, Tibet wine and black alum solution), etc. The mercury and treated sulphur are mixed and ground, and mercury powder is made. The mercury powder can be used as medicines for curing various diseases, such as poisoning, impotence, apoplexy, leprosy, epilepsy, hypertension and nervous system disease. The mercury powder has following functions of prolonging life, tonifying blood, activating blood, etc. The mercury powder has better cure effect. A serious palsy patient can be healed in three months.
BACKGROUND: Age-related hearing loss (ARHL) is a general term used to describe the sensorineural type of hearing loss occurring in both ears in older adults. Neurotrophins are the most promising candidates for supporting the auditory nerve by increasing neuronal survival. This study aimed to help elucidate the pathophysiology of ARHL by determining whether any relationship exists between brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) levels in serum samples from patients diagnosed with ARHL.
MATERIALS AND METHOD: Seventy-seven individuals, a study group of 41 patients diagnosed with ARHL, and a control group of 36 participants without hearing loss were evaluated. Serum samples were collected and used to measure serum BDNF and NT-3 levels with the new Nepenthe enzyme-linked immunosorbent assay method.
RESULTS: Median pure-tone average results in the 2000, 4000, and 6000 Hz ranges were 52.5 (44.3-67.3) dB HL in the ARHL group and 13.5 (11.1-17.1) dB HL in the control group. The difference was statistically significant (p = .001). Although NT-3 and BDNF levels were both lower in ARHL patients than in participants without hearing loss, only the BDNF levels were significantly (p = .002) lower. Mean left and right ear word recognition scores were also lower in ARHL patients than in control groups. The ARHL group was further divided into two subgroups based on word recognition scores to evaluate significant differences in BDNF and NT-3 levels. No statistically significant difference was observed in BDNF and NT-3 levels between these subgroups. However, there was a significant difference in word recognition scores.
CONCLUSIONS: Low BDNF levels in the ARHL group suggest that BDNF may play a role in the pathogenesis of ARHL. Patients with low (ARHL1) and high (ARHL2) word recognition scores were compared for the first time in the literature in terms of BDNF and NT-3 levels. However, the results were not statistically significant. This article is a preliminary study and was written to provide guidance for our next comprehensive project.
FIELD: medicinal genetics. SUBSTANCE: the present innovation deals with filamentous phage particles with ligands on their surface. These particles are used to deliver therapeutic gene to cells. Ligand is the protein developed at fusion to phage capsid protein covalently conjugated with phage particles. EFFECT: increased number of gene therapeutic preparations. 45 cl, 9 dwg, 9 ex, 1 tbl
Current assessment of lymphoedema consists of measuring volume changes objectively by a tape measure or water displacement. Early recognition of pre-clinical changes of interstitial fluid congestion in a limb at risk concerning lymph transport capacity is crucial. Objective measurement of extracellular fluids with bio-impedance spectroscopy can detect these early signs of lymphoedema. Multi Frequency Bioelectrical Impedance Analysis is completely non-invasive, highly reproducible (Ward et al 1997), highly sensitive (Cornish et al 2001), highly specific (Cornish et al 2001) and can be repeated as frequently as desired. BIS demonstrated excellent inter- and intra-rater reliability. All measures are highly reliably in women with and without lymphoedema (Szerniec et al 2010). For women with lymphoedema BIS detected a difference in the ECF in limbs which were not reflected in a corresponding difference in limb volume. This finding suggests that BIS may be particularly useful in the early detection of lymphoedema, before there is any volume change (Szerniez et al 2010). The mean ratio of extra cellular water (ECW) to intracellular water (ICW) is 1,5:1 (Ward et al 2009). Cornish et al (2001) predicted the onset of the condition up to 10 months before the condition could be clinically diagnosed. This is considerable shorter than the mean delay time of 3,5 years reported by National Summit on Lymphoedema, Adelaide 2000. The only risk factor identified as contributing to an increased risk of developing secondary lymphoedema was an increasing BMI which is consistent with previous reports (Box et al 2002).

Early detection with BIS is supposed possible even before clinical signs of swelling are available.

In this study we want to study this hypothesis and as control-group patients treated for colorectal carcinoma.
Dietary supplement: Control drink As control, subjects are asked to consume 150 ml control drink containing equal amount of insoluble fiber (cellulose) and sugar for 28 days. In addition, on days-1 and 28, subjects will receive an acute challenge of placebo drink at our clinical facility. After 30 min. control drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
Optimum extraction of the salt contents of highly concentrated thermal waters involves two procedures. Solutions of cpds. tending to form deposits and of prolonged crystallisation periods are passed through ion exchange columns. Solutions contg. readily crystallisable cpds. are concentrated to saturation pt. and treated in a vacuum crystalliser which completes crystallisation in 10-20 minutes. - The ion exchange column is regenerated with an acid and the element, which contains the deposit forming cpds. is reduced in an osmotic reactor to a tenth of its original volume. Following this, the remaining aq. soln. is sprayed, in a period of approx. 12 hours, onto the the surface of the crystals obtd. in crystallisation step. The material deposited on the surface, crystallises out, while the united salts are completely dried out in a fluidising drier.
(See boxed WARNING)

Cytarabine is a potent bone marrow suppressant. Therapy should be started cautiously in patients with pre-existing drug-induced bone marrow suppression. Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily. Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood. Facilities should be available for management of complications, possibly fatal, of bone marrow suppression (infection resulting from granulocytopenia and other impaired body defenses, and hemorrhage secondary to thrombocytopenia). One case of anaphylaxis that resulted in acute cardiopulmonary arrest and required resuscitation has been reported. This occurred immediately after the intravenous administration of cytarabine. 

Severe and at times fatal CNS, GI and pulmonary toxicity (different from that seen with conventional therapy regimens of cytarabine) has been reported following some experimental dose schedules for cytarabine. These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis leading to peritonitis; sepsis and liver abscess; pulmonary edema, liver damage with increased hyperbilirubinemia; bowel necrosis; and necrotizing colitis. Rarely, severe skin rash, leading to desquamation has been reported. Complete alopecia is more commonly seen with experimental high dose therapy than with standard treatment programs using cytarabine injection. If experimental high dose therapy is used, do not use a preparation containing benzyl alcohol. 

Cases of cardiomyopathy with subsequent death have been reported following experimental high dose therapy with cytarabine in combination with cyclophosphamide when used for bone marrow transplant preparation. 

A syndrome of sudden respiratory distress, rapidly progressing to pulmonary edema and radiographically pronounced cardiomegaly has been reported following experimental high dose therapy with cytarabine used for the treatment of relapsed leukemia from one institution in 16/72 patients. The outcome of this syndrome can be fatal. 

Two patients with childhood acute myelogenous leukemia who received intrathecal and intravenous cytarabine at conventional doses (in addition to a number of other concomitantly administered drugs) developed delayed progressive ascending paralysis resulting in death in one of the two patients.
Matrix metalloproteinases (MMPs) are a class of membrane bound enzymes that are involved in the degradation of the extracellular matrix. MMP-2 and MMP-9 have been associated with the progression of cancer. It is hypothesized that an imbalance between MMPs and MMP inhibitors allows the destruction of the extracellular matrix and enhances the ability of the tumor cells to grow and metastasize. By inhibiting MMPs, it is thought that angiogenesis and metastasis can be inhibited. This is a phase I study of COL-3, an oral matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. COL-3 is a chemically modified tetracycline derivative. Patients must have clinically progressive disease documented within 1 month prior to entry to be eligible for treatment. Patients must have also failed therapy of proven efficacy for their disease and have an ECOG performance status of less than or equal to 2. Patients must be willing to travel from their home to the NIH for follow-up visits. Patients with brain metastases or primary CNS malignancies are not eligible. Concurrent therapy for their cancer (i.e., radiation therapy, chemotherapy, etc.) will preclude participation. We will be defining the maximum tolerated dose, the toxicity profile, characterizing the pharmacokinetics, and evaluating the effect of COL-3 on several biological endpoints.
Helicobacter pylori infection is the major risk factor associated with the development of gastric cancer. Currently, administration of standard antibiotic therapy combined with probiotics and postbiotics has gained significant attention in the management of H. pylori infection. In this work, the immunomodulatory effects of Lactobacillus crispatus-derived extracellular vesicles (EVs) and cell-free supernatant (CFS) were investigated on H. pylori-induced inflammatory response in human gastric adenocarcinoma (AGS) cells. L. crispatus-derived EVs were isolated by ultracentrifugation and physically characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM), and scanning electron microscopy (SEM). Furthermore, the protein content of L. crispatus-derived EVs was also evaluated by SDS-PAGE. Cell viability of AGS cells exposed to varying concentrations of EVs and CFS was assessed by MTT assay. The mRNA expression of IL-1β, IL-6, IL-8, TNF-α, IL-10, and TGF-ß genes was determined by RT-qPCR. ELISA was used for the measurement of IL-8 production in AGS cells. In addition, EVs (50 μg/mL) and CFS modulated the H. pylori-induced inflammation by downregulating the mRNA expression of IL-1β, IL-6, IL-8, and TNF-α, and upregulating the expression of IL-10, and TGF-ß genes in AGS cells. Furthermore, H. pylori-induced IL-8 production was dramatically decreased after treatment with L. crispatus-derived EVs and CFS. In conclusion, our observation suggests for the first time that EVs released by L. crispatus strain RIGLD-1 and its CFS could be recommended as potential therapeutic agents against H. pylori-triggered inflammation.
PROBLEM TO BE SOLVED: To obtain a new antitumor agent, comprising a specific phenylpropenoic acid derivative as an active ingredient, having high safety and hardly causing adverse effects. SOLUTION: This antitumor agent comprises a phenylpropenoic acid derivative represented by formula I (R1 is H, an alkyl or an acyl; R2 is H, OH or an acyloxy; R3 is H or an alkyl) or its salt as an active ingredient. For example, a compound represented by formula II or III is cited as the compound represented by formula I. The phenylpropenoic acid derivative represented by formula I or its salt is brought into contact with a tumorous cell to inhibit the proliferetion of the tumorous cell. The compound represented by formula I, e.g. the compound represented by formula II is prepared by reacting coumaric acid with 1-chloro-3-methyl-2-butene in an alkaline solution. The compound represented by formula 1 can readily be mass-produced and can be obtained as a homogeneous substance.
Serotonergic antidepressants, including TRINTELLIX, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, buspirone, amphetamines, and St. John's Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications (4), Drug Interactions (7.1)]. Serotonin syndrome can also occur when these drugs are used alone.

Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

The concomitant use of TRINTELLIX with MAOIs is contraindicated. In addition, do not initiate TRINTELLIX in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking TRINTELLIX, discontinue TRINTELLIX before initiating treatment with the MAOI [see Contraindications (4), Drug Interactions (7.1)].

Monitor all patients taking TRINTELLIX for the emergence of serotonin syndrome. Discontinue treatment with TRINTELLIX and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of TRINTELLIX with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.